Prognostic markers in patients who have recovered from an acute variceal bleeding: Role of HVPG measurement

Disease Markers

Volumn 31, Issue 3, 2011, Pages 165-169

  Baares, Rafael ^a   Catalina, María Vega ^a   Ripoll, Cristina ^a   Rincón, Diego ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE MONONITRATE; NADOLOL; PRAZOSIN; PROPRANOLOL;

ACUTE DISEASE; ACUTE VARICEAL BLEEDING; ARTICLE; BLEEDING; CLINICAL EVALUATION; DIZZINESS; DRUG DOSE TITRATION; HEADACHE; HEPATIC VENOUS PRESSURE GRADIENT; HUMAN; IMPOTENCE; LIVER EXAMINATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; TREATMENT RESPONSE; VARICOSIS; WEAKNESS;

EID: 81155132156     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.3233/DMA-2011-0839     Document Type: Article

References (26)

1. G. D'Amico, L. Pagliaro and J. Bosch, Pharmacological treatment of portal hypertension: an evidence-based approach, Semin Liver Dis 19 (1999), 475-505. (Pubitemid 30032646)
2. R.J. Groszmann and S.Wongcharatrawee, The hepatic venous pressure gradient: anything worth doing should be done right, Hepatology 39 (2004), 280-282. (Pubitemid 38222164)
3. R.J. Groszmann, J. Bosch, N.D. Grace, H.O. Conn, G. Garcia- Tsao, M. Navasa, J. Alberts et al., Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage, Gastroenterology 99 (1990), 1401-1407. (Pubitemid 20381877)
4. U. Thalheimer, M. Mela, D. Patch and A.K. Burroughs, Targeting portal pressure measurements: a critical reappraisal, Hepatology 39 (2004), 286-290. (Pubitemid 38222166)
5. U. Thalheimer, M. Mela, D. Patch and A.K. Burroughs, Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence, Gut 53 (2004), 143-148. (Pubitemid 38083023)
6. G. D'Amico, J.C. Garcia-Pagan, A. Luca and J. Bosch, Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review, Gastroenterology 131 (2006), 1611-1624. (Pubitemid 44708947)
7. A. Albillos, R. Banares, M. Gonzalez, C. Ripoll, R. Gonzalez, M.V. Catalina and L.M. Molinero, Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis, Am J Gastroenterol 102 (2007), 1116-1126. (Pubitemid 46698256)
8. J. Turnes, M. Hernandez-Guerra, J.G. Abraldes, P. Bellot, R. Oliva, J.C. Garcia-Pagan and J. Bosch, Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis, Hepatology 43 (2006), 34-41. (Pubitemid 43733589)
9. A. Escorsell, J.M. Bordas, B. Castaneda, J. Llach, J.C. Garcia- Pagan, J. Rodes and J. Bosch, Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension, Hepatology 31 (2000), 1061-1067. (Pubitemid 30233229)
10. V. La Mura, J.G. Abraldes, S. Raffa, O. Retto, A. Berzigotti, J.C. Garcia-Pagan and J. Bosch, Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension, J Hepatol 51 (2009), 279-287.
11. C. Villanueva, C. Aracil, A. Colomo, V. Hernandez-Gea, J.M. Lopez-Balaguer, C. Alvarez-Urturi, X. Torras et al., Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding, Gastroenterology 137 (2009), 119-128.
12. J.C. Garcia-Pagan, K. Caca, C. Bureau, W. Laleman, B. Appenrodt, A. Luca, J.G. Abraldes et al., Early use of TIPS in patients with cirrhosis and variceal bleeding, N Engl J Med 362 (2010), 2370-2379.
13. R. de Franchis, Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop onmethodology of diagnosis and therapy in portal hypertension, J Hepatol 43 (2005), 167-176. (Pubitemid 40805288)
14. B. Bernard, D. Lebrec, P. Mathurin, P. Opolon and T. Poynard, Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: ameta-analysis, Hepatology 25 (1997), 63-70. (Pubitemid 27014986)
15. J.C. Garcia-Pagan, F. Feu, J. Bosch and J. Rodes, Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study, Ann Intern Med 114 (1991), 869-873.
16. C. Bureau, J.M. Peron, L. Alric, J. Morales, J. Sanchez, K. Barange, J.L. Payen et al., "A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding, Hepatology 36 (2002), 1361-1366. (Pubitemid 35403526)
17. A. Albillos, J.L. Lledo, R. Banares, I. Rossi, J. Iborra, J.L. Calleja, A. Garrido et al., Hemodynamic effects of alphaadrenergic blockade with prazosin in cirrhotic patients with portal hypertension, Hepatology 20 (1994), 611-617. (Pubitemid 24271268)
18. A.Albillos, J.C.Garcia-Pagan, J. Iborra, J.C. Bandi, G. Cacho, M. Perez-Paramo, A. Escorsell et al., Propranolol plus prazosin compared with propranolol plus isosorbide-5- mononitrate in the treatment of portal hypertension, Gastroenterology 115 (1998), 116-123. (Pubitemid 28307295)
19. C. Villanueva, C. Aracil, A. Colomo, J.M. Lopez-Balaguer, M. Piqueras, B. Gonzalez, X. Torras et al., Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient-guided pharmacological therapy, Aliment Pharmacol Ther 29 (2009), 397-408.
20. A. Gonzalez, S. Augustin, M. Perez, J. Dot, E. Saperas, A. Tomasello, A. Segarra et al., Hemodynamic response-guided therapy for prevention of variceal rebleeding: an uncontrolled pilot study, Hepatology 44 (2006), 806-812. (Pubitemid 46489543)
21. J.C. Garcia-Pagan, C. Villanueva, A. Albillos, R. Banares, R. Morillas, J.G. Abraldes and J. Bosch, Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomized controlled trial, Gut 58 (2009), 1144-1150.
22. R. Banares, E. Moitinho, B. Piqueras, M. Casado, J.C. Garcia- Pagan, A. de Diego and J. Bosch, Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis, Hepatology 30 (1999), 79-83. (Pubitemid 29300572)
23. R. Banares, E. Moitinho, A. Matilla, J.C. Garcia-Pagan, J.L. Lampreave, C. Piera, J.G. Abraldes et al., Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis, Hepatology 36 (2002), 1367-1373. (Pubitemid 35403527)
24. D. Tripathi, J.W. Ferguson, N. Kochar, J.A. Leithead, G. Therapondos, N.C. McAvoy, A.J. Stanley et al., Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed, Hepatology 50 (2009), 825-833.
25. P. Tandon, J.G. Abraldes, A. Berzigotti, J.C. Garcia-Pagan and J. Bosch, Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and metaanalysis, J Hepatol 53, 273-282.
26. J.G.Abraldes, A.Albillos, R. Banares, J. Turnes, R. Gonzalez, J.C. Garcia-Pagan and J. Bosch, Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial, Gastroenterology 136 (2009), 1651-1658.